Filtered By:
Condition: Ischemic Stroke
Management: Hospitals
This page shows you your search results in order of date. This is page number 19.
Order by Relevance | Date
Total 2377 results found since Jan 2013.
CHA2DS2-VASc score as a prognostic indicator in patients with atrial fibrillation undergoing coronary stenting
This study aimed to assess the accuracy of CHA2DS2-VASc score for predicting and grading adverse clinical outcomes in this population.METHODS: We reviewed the clinical data of all patients with previously documented nonvalvular AF who underwent coronary stenting between January 2010 and June 2015 in 12 hospitals of Beijing, China. The study population was divided into three groups: 1) Low CHA2DS2-VASc score, ≦ 2 points, 2) Intermediate score, 3-4 points, and 3) High score, ≧ 5 points. Major adverse cardiac/cerebrovascular events (MACCE) were defined as a composite of all-cause death, nonfatal myocardial infarction, rep...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Jian-Yong Zheng Dong-Tao Li Yi-Gang Q ıu Yi-Xiong Huang Zheng-Ming Xu Li Zhao Yu Chen Yi Cao Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yan J ıao Tian-Chang Li Source Type: research
Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research
CHA2DS2-VASc score as a prognostic indicator in patients with atrial fibrillation undergoing coronary stenting
This study aimed to assess the accuracy of CHA2DS2-VASc score for predicting and grading adverse clinical outcomes in this population.METHODS: We reviewed the clinical data of all patients with previously documented nonvalvular AF who underwent coronary stenting between January 2010 and June 2015 in 12 hospitals of Beijing, China. The study population was divided into three groups: 1) Low CHA2DS2-VASc score, ≦ 2 points, 2) Intermediate score, 3-4 points, and 3) High score, ≧ 5 points. Major adverse cardiac/cerebrovascular events (MACCE) were defined as a composite of all-cause death, nonfatal myocardial infarction, rep...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Jian-Yong Zheng Dong-Tao Li Yi-Gang Q ıu Yi-Xiong Huang Zheng-Ming Xu Li Zhao Yu Chen Yi Cao Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yan J ıao Tian-Chang Li Source Type: research
Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research
CHA2DS2-VASc score as a prognostic indicator in patients with atrial fibrillation undergoing coronary stenting
This study aimed to assess the accuracy of CHA2DS2-VASc score for predicting and grading adverse clinical outcomes in this population.METHODS: We reviewed the clinical data of all patients with previously documented nonvalvular AF who underwent coronary stenting between January 2010 and June 2015 in 12 hospitals of Beijing, China. The study population was divided into three groups: 1) Low CHA2DS2-VASc score, ≦ 2 points, 2) Intermediate score, 3-4 points, and 3) High score, ≧ 5 points. Major adverse cardiac/cerebrovascular events (MACCE) were defined as a composite of all-cause death, nonfatal myocardial infarction, rep...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Jian-Yong Zheng Dong-Tao Li Yi-Gang Q ıu Yi-Xiong Huang Zheng-Ming Xu Li Zhao Yu Chen Yi Cao Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yan J ıao Tian-Chang Li Source Type: research
Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research
CHA2DS2-VASc score as a prognostic indicator in patients with atrial fibrillation undergoing coronary stenting
This study aimed to assess the accuracy of CHA2DS2-VASc score for predicting and grading adverse clinical outcomes in this population.METHODS: We reviewed the clinical data of all patients with previously documented nonvalvular AF who underwent coronary stenting between January 2010 and June 2015 in 12 hospitals of Beijing, China. The study population was divided into three groups: 1) Low CHA2DS2-VASc score, ≦ 2 points, 2) Intermediate score, 3-4 points, and 3) High score, ≧ 5 points. Major adverse cardiac/cerebrovascular events (MACCE) were defined as a composite of all-cause death, nonfatal myocardial infarction, rep...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Jian-Yong Zheng Dong-Tao Li Yi-Gang Q ıu Yi-Xiong Huang Zheng-Ming Xu Li Zhao Yu Chen Yi Cao Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yan J ıao Tian-Chang Li Source Type: research
Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research
CHA2DS2-VASc score as a prognostic indicator in patients with atrial fibrillation undergoing coronary stenting
This study aimed to assess the accuracy of CHA2DS2-VASc score for predicting and grading adverse clinical outcomes in this population.METHODS: We reviewed the clinical data of all patients with previously documented nonvalvular AF who underwent coronary stenting between January 2010 and June 2015 in 12 hospitals of Beijing, China. The study population was divided into three groups: 1) Low CHA2DS2-VASc score, ≦ 2 points, 2) Intermediate score, 3-4 points, and 3) High score, ≧ 5 points. Major adverse cardiac/cerebrovascular events (MACCE) were defined as a composite of all-cause death, nonfatal myocardial infarction, rep...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Jian-Yong Zheng Dong-Tao Li Yi-Gang Q ıu Yi-Xiong Huang Zheng-Ming Xu Li Zhao Yu Chen Yi Cao Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yan J ıao Tian-Chang Li Source Type: research
Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research
CHA2DS2-VASc score as a prognostic indicator in patients with atrial fibrillation undergoing coronary stenting
This study aimed to assess the accuracy of CHA2DS2-VASc score for predicting and grading adverse clinical outcomes in this population.METHODS: We reviewed the clinical data of all patients with previously documented nonvalvular AF who underwent coronary stenting between January 2010 and June 2015 in 12 hospitals of Beijing, China. The study population was divided into three groups: 1) Low CHA2DS2-VASc score, ≦ 2 points, 2) Intermediate score, 3-4 points, and 3) High score, ≧ 5 points. Major adverse cardiac/cerebrovascular events (MACCE) were defined as a composite of all-cause death, nonfatal myocardial infarction, rep...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Jian-Yong Zheng Dong-Tao Li Yi-Gang Q ıu Yi-Xiong Huang Zheng-Ming Xu Li Zhao Yu Chen Yi Cao Yi-Da Tang Cheng-Jun Guo Zhi-Min Ma Yong-Quan Wu Yan J ıao Tian-Chang Li Source Type: research
Rivaroxaban and apixaban in patients with atrial fibrillation; a real-world data
This study aims to analyze the real-life data of patients who were prescribed rivaroxaban and apixaban and to emphasize the points that we think will make a difference compared to randomized controlled studies.METHODS: The patients who accepted to participate in the study in whom rivaroxaban (15-20 mg) and apixaban (2.5-5 mg) were started with the diagnosis of atrial fibrillation between 01 January 2018 and 31 December 2019 and whose records were fully accessed through the hospital automation system were included in the study.RESULTS: One hundred and ninety-four (48.5%) of a total of 400 patients using rivaroxaban and apix...
Source: Turkish Journal of Medical Sciences - November 3, 2022 Category: General Medicine Authors: Onur Aslan Sinan Y ıldırım Source Type: research
